Purpose of this Study
We are doing this study to find out if an experimental drug called LYL845 (the study drug) is a safe and effective treatment for your cancer. The study drug is custom-made for each participant from their own tumor tissue.
Who Can Participate?
Eligibility
Adults ages 18-75 who:
- Are diagnosed with melanoma, NSCLC or colorectal cancer
- Have received at least one round of previous treatment
- Have tumor tissue that can be surgically removed
- Have never received treatment with a cellular therapy
For more information about who can join this study, please contact the study team at 919-681-6468
- Are diagnosed with melanoma, NSCLC or colorectal cancer
- Have received at least one round of previous treatment
- Have tumor tissue that can be surgically removed
- Have never received treatment with a cellular therapy
For more information about who can join this study, please contact the study team at 919-681-6468
What is Involved?
If you choose to join this study, you will:
- Undergo surgery to collect your tumor tissue to make the study drug
- Receive lympho-depleting chemotherapy
- Take the study drug
- Have physical exams and blood draws
- Have imaging scans (CT and/or MRI)
- Have heart tests (ECG)
- Undergo surgery to collect your tumor tissue to make the study drug
- Receive lympho-depleting chemotherapy
- Take the study drug
- Have physical exams and blood draws
- Have imaging scans (CT and/or MRI)
- Have heart tests (ECG)
Study Details
Full Title
A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults with Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies
Principal Investigator
Brent
Hanks
Protocol Number
PRO00112139
NCT ID
NCT05573035
Phase
I
Enrollment Status
OPEN TO ACCRUAL